Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioma 2 Glioblastoma 2 Recurrence 1 Papillomavirus Infections 1 Medulloblastoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Human Papillomavirus-Related Cervical Carcinoma 1 Astrocytoma 1 Advanced Fallopian Tube Carcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 29 Papillomavirus Vaccines 22 Vaccines 11 Human Papillomavirus Recombinant Vaccine nonavalent 11 Radiotherapy, Intensity-Modulated 7 Human Papillomavirus DNA Tests 7 Colposcopy 7 Cisplatin 7 Educational Status 6 Carboplatin 6 Blood Specimen Collection 6 Vaccines, Synthetic 5 Specimen Handling 5 Early Intervention, Educational 5 Vaginal Smears 4 Methods 4 Engerix-B 4 fludarabine 3 epigallocatechin gallate 3 artesunic acid 3 artemisinin 3 Watchful Waiting 3 Surveys and Questionnaires 3 Patient Navigation 3 Paclitaxel 3 Imiquimod 3 Hepatitis A Vaccines 3 Cyclophosphamide 3 halofantrine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Papillomavirus Infections × Diphtheria Toxoid × Clear all

NCT03180034 2025-09-04

ESCUDDO

National Cancer Institute (NCI)

Phase 4 Active not recruiting

27,945 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡